AMY-101 TFA

Description: AMY-101 TFA is a cyclic peptide that acts as an inhibitor of complement C3 and an immunomodulator, used for the treatment of gingivitis and periodontitis. It significantly reduces inflammation and lowers levels of MMP-8 and MMP-9. AMY-101 TFA also has a mitigating effect on lung inflammation/damage in patients with COVID-19-induced ARDS and acute kidney injury associated with SARS-CoV-2. Target: SARS-CoV, MMP, Complement System. Smiles: C(C(O)=O)(F)(F)F.C(C=1C=2C(N(C)C1)=CC=CC2)[C@H]3C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=4C=5C(NC4)=CC=CC5)C(=O)N(C)CC(=O)N[C@@H](C)C(=O)N[C@@H](CC6=CN=CN6)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(N([C@@H]([C@H](CC)C)C(N)=O)C)=O)CSSC[C@H](NC([C@@H](NC([C@@H](CC7=CC=C(O)C=C7)N)=O)[C@H](CC)C)=O)C(=O)N[C@@H]([C@@H](C)C)C(=O)N3. References: Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450.